# Pharmacokinetics of Twice or Once Daily DTG (50mg) in Children With HIV and TB

> **NCT04746547** · PHASE4 · UNKNOWN · sponsor: **University of KwaZulu** · enrollment: 20 (estimated)

## Conditions studied

- Tuberculosis
- Hiv

## Interventions

- **DRUG:** Dolutegravir 50 MG
- **DRUG:** Dolutegravir 10 MG

## Key facts

- **NCT ID:** NCT04746547
- **Lead sponsor:** University of KwaZulu
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-19
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-07-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-02-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04746547

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04746547, "Pharmacokinetics of Twice or Once Daily DTG (50mg) in Children With HIV and TB". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04746547. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*